Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 3, 2006, Pages 272-281

  Khalili, Barzin ^a,b   Bahna, Sami L ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FAS ANTIGEN; FAS LIGAND; GRANZYME B; IMMUNOGLOBULIN; PERFORIN;

APOPTOSIS; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG MECHANISM; EPIDERMIS CELL; EPITHELIZATION; HUMAN; MEDLINE; PATHOGENESIS; PEER REVIEW; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS;

EID: 33749182972     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60789-2     Document Type: Review

References (70)

1. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94:419-436.
2. Paquet P, Piérard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol. 2005;136:205-216.
3. Bottinger LE, Strandberg I, Westerholm B. Drug induced febrile mucocutaneous syndrome. Acta Med Scand. 1975;198:229-233.
4. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol. 1990;126:1103-1104.
5. Schōpf E, Stūhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991;127:839-842.
6. Strom BL, Carson JL, Halpern AC. A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposure. Arch Dermatol. 1991;127:831-838.
7. Leehutaphong V, Sivayathon A, Suthipinittharm P, Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol. 1993;32:428-431.
8. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
9. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981 - 1985. Arch Dermatol. 1990;126:37-42.
10. Parsons JM. Management of toxic epidermal necrolysis. Cutis. 1985;36:305-307, 310-311.
11. Sheretz EF, Jegasothy BV, Lazarus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol. 1985;12:178-181.
12. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy. 1994;73:27-34.
13. Kim PS, Goldfarb IW, Gaisford JC, Slater H. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil. 1983;4:91-100.
14. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed with corticosteroids. Ann Surg. 1986;204:503-512.
15. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710-714.
16. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
17. Viard-Leveugle I, Bullani RR, Meda P, et al. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem. 2003;278:16183-16188.
18. Nassif A, Bensussan A, Dorothée G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118:728-733.
19. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perform, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109:155-161.
20. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Piérard GE. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605-608.
21. Lerner LH, Qureshi AA, Reddy BV, Lerner EA. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol. 2000;114:196-199.
22. Iwai K, Miyawaki T, Takizawa T, Konno A, et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 1994;84:1201-1208.
23. Paquet P, Piérard GE. Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med. 2002;10:145-147.
24. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004;123:850-855.
25. Berthou C, Michel L, Soulie A, et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol. 1997;159:5293-5300.
26. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson Syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515-1520.
27. Schnyder B, Frutig K, Mauri-Hellwig D, Limat A, Yawalker N, Pichler WJ. T-cell mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clin Exp Allergy. 1998;28:1412-1417.
28. Mauri-Hellwig D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol. 1995;155:462-472.
29. Zanni MP, von Greyerz S, Schnyder B et al. HLA-restricted processing and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest. 1998;102:1591-1598.
30. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114:1209-1215.
31. Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol. 2000;142:191-192.
32. Paquet P, Jacob E, Damas P, Piérard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns. 2001;27:652-655.
33. Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2003;91:86-91.
34. Sidwell RU, Swift S, Yan CL, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. Int J Clin Practice. 2003;57:643-645.
35. Simeone F, Rubio ER. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. J La State Med Soc. 2003;155:266-269.
36. Ito K, Hara H, Okada T, Shimjima H, Suzuki H. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-Ligand expression [letter]. Clin Exp Dermatol. 2004;29:679-680.
37. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504-510.
38. Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci. 2005;329:95-98.
39. Prassad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIG) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIG involving the Fas apoptotic pathway. J Immunol. 1998;161:3781-3790.
40. Ekberg C, Nordstrom E, Skansen-Saphir U, et al. Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival. Hum Immunol. 2001;62:215-227.
41. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33-36.
42. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol. 2003;139:39-43.
43. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.
44. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.
45. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson Syndrome. J Rheumatol. 2000;27:2494-2497.
46. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47:548-552.
47. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 2003;112:1430-1436.
48. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71:398-400.
49. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003;83:430-432.
50. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol. 2005;32:1-6.
51. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246-255.
52. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-88.
53. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol. 2004;83:661-665.
54. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology. 2001;203:45-49.
55. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology. 2003;207:96-99.
56. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43:847-851.
57. Ducic I, Shalom A, Rising W, Nagamoto K, Munster AM. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg. 2002;110:768-773.
58. Shevach EM. The effects of Cyclosporin A on the immune system. Ann Rev Immunol. 1985;3:397-423.
59. Paquet P, Piérard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology. 1999;198:198-202.
60. Renfro L, Grant-Kels JM, Daman LA. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol. 1989;28:441-444.
61. Hewitt J, Ormerod AD. Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol. 1992;17:264-265.
62. Zaki I, Patel S, Reed R, Dalziel KL. Toxic epidermal necrolysis associated with severe hypocalcemia, and treated with cyclosporin. Br J Dermatol. 1995;133:337-338.
63. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol. 1996;37:208-212.
64. Jarrett P, Ha T, Snow J. Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol. 1997;22:254.
65. Jarrett P, Rademaker M, Havill J, Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol. 1997;22:146-147.
66. Szepietowski J, Wasik F, Szybejko-Machaj G, Maj J. Toxic epidermal necrolysis successfully treated with cyclosporin: report of three cases. J Eur Acad Dermatol and Venereol. 1997;9:169-172.
67. Robak E, Robak T, Gora-Tybor J, et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med. 2001:32:31-39.
68. Yung A, Agnew K, Snow J, Oliver F. Two unusual cases of toxic epidermal necrolysis. Australas J Dermatol. 2002;43:35-38.
69. Arévalo JA, Lorente JA, González-Herrada C, Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-478.
70. Paquet P, Jacob E, Damas P, Pirson J, Piérard G. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res. 2005;297:266-273.